Larimar Therapeutics, Inc. (LRMR)
NASDAQ:LRMR
Want to see LRMR full AI Analyst Report?
LRMR Stock Chart & Stats
$4.80
-$0.11(-2.78%)
At close: 4:00 PM EST
$4.80
-$0.11(-2.78%)
Day’s Range― - ―
52-Week Range$2.22 - $6.42
Previous CloseN/A
Volume147.46K
Average Volume (3M)1.93M
Market Cap
$372.94M
Enterprise Value$116.83M
Total Cash (Recent Filing)$200.38M
Total Debt (Recent Filing)$3.78M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Aug 06, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.10
Shares Outstanding103,882,935
10 Day Avg. Volume2,150,539
30 Day Avg. Volume1,927,435
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)3.56
Price to Sales (P/S)0.00
P/FCF Ratio-2.45
Enterprise Value/Market Cap0.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.71
Forecast
1Y Price Target
$15.00Price Target Upside212.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.66
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory ProgressBreakthrough designation and formal FDA alignment on endpoints materially lower regulatory risk and can compress timelines. A planned rolling BLA plus mid‑2026 Phase 3 start create a clear, near‑term development roadmap that raises the probability of achieving approval and commercial viability if trials confirm benefit.
Biomarker / Scientific ValidationPublished cross‑species evidence that nomlabofusp increases frataxin and supports skin FXN as a surrogate strengthens the drug’s biological rationale and regulatory case. Robust biomarker validation can shorten trials, reduce sample sizes, and create a durable scientific moat for a first‑in‑class mitochondrial delivery approach.
Near‑term Funding RunwayPost‑offering cash of roughly $200M provides multi‑quarter funding to execute a rolling BLA submission and initiate a global Phase 3, reducing immediate financing pressure. This capital buffer supports milestone delivery and de‑risks near‑term development execution compared with similarly situated pre‑revenue peers.
Bears Say
Pre‑revenue OperationsAs a clinical‑stage biotech with no product revenue and materially larger TTM losses, Larimar cannot self‑fund operations. Long‑term viability depends on clinical/regulatory success and eventual commercialization; absent approval, the company remains structurally reliant on external capital and partner deals.
Accelerating Cash BurnOperating cash flow deterioration shows accelerating cash consumption as development scales toward Phase 3 and BLA activities. Rising burn shortens runway, increases probability of further financings, and elevates execution risk by tying strategy to the company’s ability to access capital markets or partners over the medium term.
Dilution / Reliance On EquityApproval to nearly double authorized shares and a recent equity offering indicate structural dependence on equity financing. That reliance raises dilution risk for existing investors and means future access to capital markets will materially affect long‑term ownership, governance dynamics, and the company’s strategic flexibility.
Larimar Therapeutics News
LRMR FAQ
What was Larimar Therapeutics, Inc.’s price range in the past 12 months?
Larimar Therapeutics, Inc. lowest stock price was $2.22 and its highest was $6.42 in the past 12 months.
What is Larimar Therapeutics, Inc.’s market cap?
Larimar Therapeutics, Inc.’s market cap is $372.94M.
When is Larimar Therapeutics, Inc.’s upcoming earnings report date?
Larimar Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 50 days.
How were Larimar Therapeutics, Inc.’s earnings last quarter?
Larimar Therapeutics, Inc. released its earnings results on May 14, 2026. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.535 by $0.225.
Is Larimar Therapeutics, Inc. overvalued?
According to Wall Street analysts Larimar Therapeutics, Inc.’s price is currently Undervalued.
Does Larimar Therapeutics, Inc. pay dividends?
Larimar Therapeutics, Inc. does not currently pay dividends.
What is Larimar Therapeutics, Inc.’s EPS estimate?
Larimar Therapeutics, Inc.’s EPS estimate is -0.4.
How many shares outstanding does Larimar Therapeutics, Inc. have?
Larimar Therapeutics, Inc. has 103,882,935 shares outstanding.
What happened to Larimar Therapeutics, Inc.’s price movement after its last earnings report?
Larimar Therapeutics, Inc. reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.535. Following the earnings report the stock price went down -5.122%.
Which hedge fund is a major shareholder of Larimar Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LRMR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Larimar Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.00 (212.50% Upside)
$15.00 (212.50% Upside)
Blogger Sentiment
Bullish
LRMR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 8.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
24.65%
12-Months-Change
Fundamentals
Return on Equity
-134.14%
Trailing 12-Months
Asset Growth
22.53%
Trailing 12-Months
Company Description
Larimar Therapeutics, Inc.
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
LRMR Stock 12 Month Forecast
Average Price Target
$15.00
▲(212.50% Upside)
Technical Analysis
Omeros
―
Vanda
―
Foghorn Therapeutics
―
Candel Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
35.94% Insiders
4.88% Mutual Funds
11.48% Other Institutional Investors
41.38% Public Companies and Individual Investors